XLock Biosciences, LLC (XL) develops novel engineered chemokine proteins that have therapeutic utility through well-understood biological mechanisms. XL’s lead compound, CCL20 Locked Dimer has demonstrated efficacy in preclinical animal models for psoriasis and psoriatic arthritis. Ongoing SBIR Phase II R&D continues to de-risk our lead molecule by establishing preclinical safety and therapeutic efficacy in plaque psoriasis.